Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Naquotinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 10/20 | 1.00 |
| ▸ | RET | P07949 | 9/20 | 0.62 |
| ▸ | ROS1 | P08922 | 9/20 | 0.62 |
| ▸ | FLT3 | P36888 | 9/20 | 0.62 |
| ▸ | EML4 | Q9HC35 | 8/20 | 0.62 |
| ▸ | ALK | Q9UM73 | 8/20 | 0.62 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.51 |
| ▸ | PLK4 | O00444 | 1/20 | 0.51 |
| ▸ | CIT | O14578 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
| ▸ | GAK | O14976 | 1/20 | 0.51 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.51 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.51 |
| ▸ | BUB1 | O43683 | 1/20 | 0.51 |
| ▸ | SNRNP200 | O75643 | 1/20 | 0.51 |
| ▸ | STK16 | O75716 | 1/20 | 0.51 |
| ▸ | STK10 | O94804 | 1/20 | 0.51 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.51 |
| ▸ | LATS1 | O95835 | 1/20 | 0.51 |
| ▸ | SLC25A5 | P05141 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Naquotinib SCHEMBL29355759 | 1.00 | EGFR (1.00) | EGFRRETROS1FLT3EML4 | |
| Naquotinib SCHEMBL19921009 | 1.00 | EGFR (1.00) | EGFRRETROS1FLT3EML4 | |
| Naquotinib SCHEMBL29409491 | 0.97 | EGFR (0.95) | EGFRRETROS1FLT3EML4 | |
| Naquotinib SCHEMBL18687011 | 0.97 | EGFR (0.95) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16195821 | 0.96 | EGFR (1.00) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16207133 | 0.96 | EGFR (0.93) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16196142 | 0.94 | EGFR (0.89) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16207004 | 0.94 | EGFR (0.89) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16258225 | 0.94 | EGFR (0.89) | EGFRRETROS1FLT3EML4 | |
| SCHEMBL16207170 | 0.93 | EGFR (0.87) | EGFRRETROS1FLT3EML4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026101848-A1 | ENGINEERED KETOREDUCTASE POLYPEPTIDES AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-15 | — | — | WO | claimed |
| US-20190282569-A1 | STABLE PHARMACEUTICAL COMPOSITION | ASTELLAS PHARMA INC. (JP) | 2019-09-19 | — | — | US | claimed |
| EP-3533448-A1 | STABLE PHARMACEUTICAL COMPOSITION | Astellas Pharma Inc. (JP) | 2019-09-04 | — | — | EP | claimed |
| US-10188737-B2 | Stabilized pharmaceutical composition | ASTELLAS PHARMA INC. (JP) | 2019-01-29 | — | — | US | claimed |
| US-20180133325-A1 | STABILIZED PHARMACEUTICAL COMPOSITION | ASTELLAS PHARMA INC. (JP) | 2018-05-17 | — | — | US | claimed |
| EP-3290036-A1 | STABILIZED PHARMACEUTICAL COMPOSITION | Astellas Pharma Inc. (JP) | 2018-03-07 | — | — | EP | claimed |
| US-20170196859-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRAZINE CARBOXAMIDE COMPOUND AS ACTIVE INGREDIENT | ASTELLAS PHARMA INC. (JP) | 2017-07-13 | — | — | US | claimed |
| EP-3150206-A1 | MEDICINAL COMPOSITION COMPRISING PYRAZINE CARBOXAMIDE COMPOUND AS ACTIVE INGREDIENT | Astellas Pharma Inc. (JP) | 2017-04-05 | — | — | EP | claimed |
| EP-2805940-B1 | PYRAZINE CARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC (JP) | 2016-11-23 | — | — | EP | claimed |
| US-9085540-B2 | Pyrazinecarboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-07-21 | — | — | US | claimed |
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-30 | — | — | US | claimed |
| WO-2026102212-A1 | MACROCYCLIC MCL-1 INHIBITORS | VANDERBILT UNIVERSITY (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026101848-A1 | ENGINEERED KETOREDUCTASE POLYPEPTIDES AND USES THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| WO-2026101867-A1 | PROCESS FOR PREPARING A MACROCYCLIC DIAMINE, INTERMEDIATES, AND CRYSTALLINE FORMS THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-15 | — | — | WO | disclosed |
| US-12343428-B2 | Compositions and methods for cancer treatment | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-07-01 | — | — | US | disclosed |
| US-9085540-B2 | Pyrazinecarboxamide compound | ASTELLAS PHARMA INC. (JP) | 2015-07-21 | — | — | US | disclosed |
| EP-2805940-A1 | PYRAZINE CARBOXAMIDE COMPOUND | Astellas Pharma Inc. (JP) | 2014-11-26 | — | — | EP | disclosed |
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-30 | — | — | US | disclosed |
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-30 | — | — | US | disclosed |
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140323463-A1 | PYRAZINECARBOXAMIDE COMPOUND | EGFR, ERBB2, ALK | EGFR 1/4885RET 6/4885ROS1 25/4885 |
| US-20170196859-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PYRAZINE CARBOXAMIDE COMPOUND AS ACTIVE INGREDIENT | BTK, JAK3, JAK2 | EGFR 286/4885RET 127/4885ROS1 242/4885 |
| US-20180133325-A1 | STABILIZED PHARMACEUTICAL COMPOSITION | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, WASHC5, ALB | EGFR 3365/4885RET 3733/4885ROS1 4413/4885 |
| US-20190282569-A1 | STABLE PHARMACEUTICAL COMPOSITION | KCNK5, KCNJ2, KCNJ11 | EGFR 2604/4885RET 2553/4885ROS1 4240/4885 |
| US-10188737-B2 | Stabilized pharmaceutical composition | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, WASHC5, ALB | EGFR 3365/4885RET 3733/4885ROS1 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.